Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 27, 2021

Fulvestrant–Palbociclib vs Letrozole–Palbociclib as Initial Therapy for Endocrine-Sensitive, HR-Positive, ERBB2-Negative Advanced Breast Cancer

JAMA Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial
JAMA Oncol 2021 Oct 07;[EPub Ahead of Print], A Llombart-Cussac, JM Pérez-García, M Bellet, F Dalenc, M Gil-Gil, M Ruíz-Borrego, J Gavilá, M Sampayo-Cordero, E Aguirre, P Schmid, F Marmé, S Di Cosimo, J Gligorov, A Schneeweiss, J Albanell, P Zamora, D Wheatley, E Martínez-de Dueñas, K Amillano, A Malfettone, J Cortés

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading